Modafinil (Provigil®)

Modafinil (US brand name Provigil® and generic) is a wakefulness promoting agent. Here is key information about this medication. FDA-approved indications To improve wakefulness in adult patients with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD) Dosage 1. Adults Narcolepsy or OSA: 200 mg once daily in the morning Shift work disorder: 200 […]

How to Screen for Sleep Apnea

    To screen for Obstructive Sleep Apnea, we need to check for multiple factors. The STOP-Bang questionnaire looks at these multiple factors. A link to information about the questionnaire is provided below.       1. Snoring Ask the patient and the person who sleeps in the same room. But, many of our patients […]

New warning about aripiprazole

The FDA issued a warning on May 3, 2016 about aripiprazole stating that “compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of aripiprazole (Abilify®, Abilify Maintena®, Aristada®, and generics). These uncontrollable urges were reported to have stopped when the medicine was discontinued or the dose […]

Olanzapine (Zyprexa®)

Olanzapine (US brand name Zyprexa® and generic) is a second-generation (atypical) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. As oral formulation for: a. Schizophrenia in adults and adolescents b. Manic or mixed episodes associated with bipolar I disorder in adults and adolescents (ages 13-17 ) c. Manic or mixed episodes associated […]

Paliperidone (Invega®)

Paliperidone extended-release (US brand name Invega® and generic) is a second-generation (“atypical”) antipsychotic. FDA-approved indications 1. Treatment of schizophrenia in adults and adolescents (ages 12-17) 2. Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. Dosage A. Schizophrenia (adults) Initial: 6 mg/day Recommended: 3 – 12 mg/day […]

Risperidone (Risperdal®)

Risperidone (US brand name Risperdal® and generic) is a second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. Treatment of schizophrenia 2. As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder 3. Treatment of irritability associated with autistic disorder […]

Risperidone long-acting (Risperdal Consta®)

Risperdal Consta® is a long-acting injectable formulation of risperidone, a second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-Approved Indications Schizophrenia Monotherapy for the maintenance treatment of Bipolar I Disorder Adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder. Disadvantages Requires refrigeration Administered every 2 weeks rather than […]

3-month paliperidone palmitate (Invega Trinza®)

Paliperidone palmitate (Invega Trinza®) is an extended-release injectable second-generation (“atypical”) antipsychotic which can be administered once every 3 months. Here is basic information about this medication. FDA-Approved Indication Schizophrenia after adequate treatment with 1-month paliperidone palmitate extended-release (Invega Sustenna®) for at least four months. Dosage The dose of 3-month paliperidone palmitate (Invega Trinza®) will depend on the last […]

Paliperidone palmitate (Invega Sustenna®)

Paliperidone palmitate (Invega Sustenna®) is an extended-release injectable second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-approved indications Treatment of schizophrenia Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants Dosage A. Schizophrenia Initiation (IM deltoid): Administer 234 mg on day 1; 156 mg on day 8 Monthly […]

Extended Release Olanzapine (Zyprexa Relprevv®)

Extended Release Olanzapine (Zyprexa Relprevv®) is a long-acting, second-generation (atypical), injectable antipsychotic. Here is basic information about this medication. FDA-approved indications Schizophrenia Dosage Recommended dosing of extended release olanzapine based on correspondence to oral olanzapine doses A. First 8 weeks of treatment a) Target oral dose 10 mg/day: 210 mg/2 weeks or 405 mg/4 weeks b) Target oral […]

Haloperidol (Haldol® Decanoate)

Haldol® Decanoate is a brand name of a depot formulation of haloperidol which is a first-generation (“typical”) antipsychotic. Here is basic information about this medication. FDA-approved indications Treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy Dosage A. Initial dosage (given by deep IM injection every month) Switchover from oral dose to haloperidol decanoate […]

Ziprasidone (Geodon®)

Ziprasidone (US brand name Geodon® and generic) is a second-generation (“atypical”) antipsychotic. FDA-approved indications A. As an oral formulation 1. Schizophrenia 2. Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder 3. Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate B. As an intramuscular injection […]

Iloperidone (Fanapt®): Basic Information

Iloperidone (US brand name Fanapt®) is a second-generation (“atypical”) antipsychotic. FDA-approved indications Treatment of adults with schizophrenia Dosage Starting: 1 mg twice daily Target: 6–12 mg twice daily (achieved by dose increments of 1–2 mg twice daily) Maximum: 12 mg twice daily (24 mg/day) Please refer to Prescribing Information (see link below) for complete discussion […]

Cariprazine (Vraylar®)

Cariprazine (Vraylar®) is a second-generation (atypical) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. Schizophrenia 2. Acute treatment of manic or mixed episodes associated with bipolar I disorder. Dosage Schizophrenia Starting: 1.5 mg/day Recommended: 1.5–6 mg/day Bipolar Mania Starting: 1.5 mg/day Recommended: 3–6 mg/day Please refer to Prescribing Information (see link below) for […]

Asenapine (Saphris®)

Asenapine (US brand name Saphris®) is a second-generation (“atypical”) antipsychotic. FDA-approved indications 1. Schizophrenia 2. Acute treatment of manic and mixed episodes associated with bipolar I disorder (monotherapy) 3. Acute treatment of manic and mixed episodes associated with bipolar I disorder (adjunctive to lithium or valproate) Dosage Schizophrenia – acute treatment in adults Starting: 5 […]

Aripiprazole (Abilify®)

Aripiprazole (US brand name Abilify® and generic Aripiprix, zolonda) is a second-or third generation (atypical) antipsychotic. FDA-approved indications A. Oral 1. Schizophrenia 2. Acute treatment of manic and mixed episodes associated with bipolar I disorder 3. Adjunctive treatment of major depressive disorder 4. Irritability associated with autistic disorder 5. Treatment of Tourette’s disorder B. Injectable […]

Haloperidol

Haloperidol (US brand name Haldol® and generic) is a first-generation (“typical”) antipsychotic. Here is basic information about this medication. Oral Haloperidol (Tablets, Oral concentrate) FDA-approved indications 1. Management of manifestations of psychotic disorders 2. Control of tics and vocal utterances of Tourette’s Disorder in children and adults 3. Treatment of severe behavior problems in children of combative, […]

Learning inforgraphs

Find more education infographics on e-Learning Infographics Find more education infographics on e-Learning Infographics Find more education infographics on e-Learning Infographics Find more education infographics on e-Learning Infographics Find more education infographics on e-Learning Infographics Find more education infographics on e-Learning Infographics

mood dys-regulation disorder: Diagnosis and Management

Professor Dr. Heba El Shehawi,Professor of Child Psychiatry,,Institute of Psychiatry,Ain Shams University,Egypt. She is giving a full lecture about mood dysregulation disorders among children, diagnosis and management. Professor Heba has a full clinical experience in the field and she is running a daily child psychiatry clinic managing different disorder.